1. Libby P, Bonow RO, Mann DL, et al. Braunwald’s Heart Disease (8th ed.). Elsevier, 2008. 2274 p.
2. Franklin SS, Pio JR, Wong ND, et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111: 1121–7.
3. McEniery CM, Yasmin, Wallace S, et al. Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. Hypertension 2005; 46: 221–6.
4. Gordeev IG, Shaydyuk OYu, Taratukhin EO. Sleep apnea syndrome and cardiovascular pathology: modern insight. Russian Journal of Cardiology 2012; 6: 5–12. Russian (Гордеев И. Г., Шайдюк О. Ю., Таратухин Е. О. Синдром апноэ во сне и кардиологическая патология: современный взгляд. Российский кардиологический журнал 2012; 6: 5–12).
5. Feig DI, Kang DH, Nakagawa T, et al. Uric acid and hypertension. Curr Hypertens Rep 2006; 8: 111–6.
6. Duprez DA. Role of renin-angiotensin-aldosterone system in vascular remodelling and inflammation. J Hypertens 2006; 24: 983–92.
7. Lüpker RV, Steffen LM, Jacobs DR Jr, et al. Trends in blood pressure and hypertension detection, treatment and control 1980–2009: the Minnesota Heart Survey. Circulation 2012; 126 (15): 1852–7.
8. Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combiation in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60: 124–30.
9. Lobanova EG, Chekalina ND. Contemporary aspects for the calcium channel blockers pharmacology. Web-publication. Russian (Лобанова ЕГ, Чекалина НД. Современные аспекты фармакологии блокаторов кальциевых каналов. Электронная публикация URL: www.rlsnet.ru/ articles_435.htm — обр. 20.01.2013).
10. Borghi C. Lercanidipine in hypertension. Vasc Health & Risk Manag 2005; 1: 173–82.
11. Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.
12. Minushkina LO, Iosava IK. Lercanidipine in arterial hypertension. Kardiologia 2012; 52: 70–4. Russian (Минушкина ЛО, Иосава ИК. Лерканидипин в лечении артериальной гипертензии. Кардиология 2012; 52: 70–4).
13. Sansanayudh N, Wongwiwatthananukit S, Veerayuthvilai S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 6: 84–92.
14. Sakurai-Yamashita Y, Harada N, Niwa M. Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell Mol Neurobiol 2011; 31: 561–7.
15. Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.
16. Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.
